Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Gnanasakthy A, Lewis SA, Clark MJ, Mordin MM, Evans E, DeMuro-Mercon CJ. The impact of primary endpoints on patient-reported outcome label claims. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012.
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.
Zhou X, Wang J, Zhang J, Zhu H. Comparison of mixed-effects model, pattern-mixture model, and selection model in estimating treatment effect using pro data in clinical trials. Poster presented at the JSM 2011; July 30, 2011. Miami Beach, FL.
McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.
Baldwin M, Spong A, Doward LC, Gnanasakthy A. Patient-reported outcomes, patient-reported information: from randomized controlled trials to the social web and beyond. Patient. 2011 Jan;4(1):11-7. doi: 10.2165
Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(5):295-8.
Neighbors DM, Candrilli SD. Concomitant medication costing using clinical trial data: a case study. Presented at the 2000 ISPOR 5th Annual International Meeting; May 2000. Arlington, VA.